Antibody–drug conjugates come of age in oncology
C Dumontet, JM Reichert, PD Senter… - Nature Reviews Drug …, 2023 - nature.com
Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the
potency of highly cytotoxic agents, potentially reducing the severity of side effects by …
potency of highly cytotoxic agents, potentially reducing the severity of side effects by …
Overview of the most promising radionuclides for targeted alpha therapy: The “hopeful eight”
Among all existing radionuclides, only a few are of interest for therapeutic applications and
more specifically for targeted alpha therapy (TAT). From this selection, actinium-225 …
more specifically for targeted alpha therapy (TAT). From this selection, actinium-225 …
Roles of podoplanin in malignant progression of tumor
H Suzuki, MK Kaneko, Y Kato - Cells, 2022 - mdpi.com
Podoplanin (PDPN) is a cell-surface mucin-like glycoprotein that plays a critical role in tumor
development and normal development of the lung, kidney, and lymphatic vascular systems …
development and normal development of the lung, kidney, and lymphatic vascular systems …
[HTML][HTML] Ferroptosis in colorectal cancer: Potential mechanisms and effective therapeutic targets
Y Wang, Z Zhang, W Sun, J Zhang, Q Xu, X Zhou… - Biomedicine & …, 2022 - Elsevier
Colorectal cancer (CRC) is a common malignant tumor characterized by unchecked division
and survival of abnormal cells in the colon or rectum with high morbidity and mortality …
and survival of abnormal cells in the colon or rectum with high morbidity and mortality …
Overview of radiolabeled somatostatin analogs for cancer imaging and therapy
R Eychenne, C Bouvry, M Bourgeois, P Loyer… - Molecules, 2020 - mdpi.com
Identified in 1973, somatostatin (SST) is a cyclic hormone peptide with a short biological half-
life. Somatostatin receptors (SSTRs) are widely expressed in the whole body, with five …
life. Somatostatin receptors (SSTRs) are widely expressed in the whole body, with five …
Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists
Peptide receptor radionuclide therapy (PRRT) has over the last two decades emerged as a
very promising approach to treat neuroendocrine tumors (NETs) with rapidly expanding …
very promising approach to treat neuroendocrine tumors (NETs) with rapidly expanding …
Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer—a systematic review and meta-analysis
Background Targeted radionuclide therapy with Actinium-225-labeled prostate-specific
membrane antigen ligands (225Ac-PSMA) has emerged as a promising treatment modality …
membrane antigen ligands (225Ac-PSMA) has emerged as a promising treatment modality …
Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy
Purpose: Radiopharmaceutical therapy is changing the standard of care in prostate cancer
and other malignancies. We previously reported high CD46 expression in prostate cancer …
and other malignancies. We previously reported high CD46 expression in prostate cancer …
Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review
Introduction Metastatic castrate resistant prostate cancer (mCPRC) remains an aggressive
form of prostate cancer that no longer responds to traditional hormonal treatment alone …
form of prostate cancer that no longer responds to traditional hormonal treatment alone …
How We Do It: A Multidisciplinary Approach to 177Lu DOTATATE Peptide Receptor Radionuclide Therapy
Lutetium 177 (177Lu) DOTA-0-Tyr3-Octreotate (DOTATATE) peptide receptor radionuclide
therapy (PRRT) is an effective treatment for advanced gastroenteropancreatic …
therapy (PRRT) is an effective treatment for advanced gastroenteropancreatic …